RSLSReShape Lifesciences Inc.

Nasdaq reshapelifesciences.com


$ 0.17 $ -0.01 (-5.19 %)    

Monday, 19-Aug-2024 10:14:22 EDT
QQQ $ 475.89 $ 0.23 (0.05 %)
DIA $ 408.64 $ 1.90 (0.47 %)
SPY $ 556.17 $ 1.28 (0.23 %)
TLT $ 98.11 $ 0.17 (0.17 %)
GLD $ 231.43 $ 1.23 (0.53 %)
$ 0.1793
$ 0.17
$ 0.19 x 1,000
-- x --
$ 0.17 - $ 0.17
$ 0.14 - $ 1.29
553,716
na
4.52M
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-01-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 04-17-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-19-2022 06-30-2022 10-Q
10 05-23-2022 03-31-2022 10-Q
11 04-08-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-12-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 07-30-2020 06-30-2020 10-Q
18 06-19-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-08-2019 09-30-2019 10-Q
21 07-24-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 02-22-2019 12-31-2018 10-K
24 11-02-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-05-2018 12-31-2017 10-K
28 11-03-2017 09-30-2017 10-Q
29 08-02-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 02-23-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reshape-lifesciences-q2-eps-006-up-from-108-yoy-sales-197m-miss-221m-estimate

Reshape Lifesciences (NASDAQ:RSLS) reported quarterly losses of $(0.06) per share. This is a 94.44 percent increase over losses...

 maxim-group-downgrades-reshape-lifesciences-to-hold

Maxim Group analyst Anthony Vendetti downgrades Reshape Lifesciences (NASDAQ:RSLS) from Buy to Hold.

 vyome-has-signed-a-merger-agreement-with-reshape-lifesciences-to-go-public-and-trade-on-the-nasdaq-capital-market-under-the-ticker-symbol-hind

Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global ma...

 reshape-lifesciences-receives-notice-of-allowance-for-us-patent-application-titled-intragastric-volume-occupying-device-and-method-for-fabricating-same-for-treating-obesity

https://patentcenter.uspto.gov/applications/16865242/ifw/docs

 why-reshape-lifesciences-stock-is-moving-higher-wednesday

ReShape Lifesciences reported that it gained approval from the United States Patent and Trademark Office for its application en...

 amid-ozempics-miracle-weight-loss-craze-this-company-peaked-over-100-in-tuesday-pre-market-after-receiving-us-patent-for-obesity-treatment

The approval comes at a time when global demand for weight loss drugs like Ozempic and WeGovy is increasing.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION